Kathleen Mary Frey

Title: Kathleen Mary Frey: Innovator in Dihydrofolate Reductase Inhibition

Introduction

Kathleen Mary Frey is a notable inventor based in Manchester, Connecticut. She has made significant contributions to the field of biochemistry, particularly in the development of inhibitors for dihydrofolate reductase (DHFR). Her work has implications for both pathogenic organisms and potential cancer therapeutics.

Latest Patents

Kathleen holds a patent for "Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase." This patent describes the design, synthesis, and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo, or heteroaryl ring. These DHFR inhibitors are potent and selective for various pathogenic organisms, including methicillin-resistant bacteria, fungi, and protozoa. Additionally, these compounds show potency against the mammalian enzyme, indicating their potential use as anti-cancer therapeutics. Kathleen has 1 patent to her name.

Career Highlights

Kathleen is affiliated with the University of Connecticut, where she continues her research and development in the field of biochemistry. Her innovative work has positioned her as a key figure in the study of DHFR inhibitors.

Collaborations

Kathleen has collaborated with notable colleagues, including Dennis L. Wright and Kishore Viswanathan. These collaborations have further enhanced her research and contributed to the advancement of her projects.

Conclusion

Kathleen Mary Frey is a pioneering inventor whose work on DHFR inhibitors holds promise for both medical and therapeutic applications. Her contributions to the field are significant and continue to impact research in biochemistry.